Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II cli… Read more
Revance Therapeutics, Inc. (RVNC) - Net Assets
Latest net assets as of September 2024: $-163.03 Million USD
Based on the latest financial reports, Revance Therapeutics, Inc. (RVNC) has net assets worth $-163.03 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($461.56 Million) and total liabilities ($624.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-163.03 Million |
| % of Total Assets | -35.32% |
| Annual Growth Rate | N/A |
| 5-Year Change | -167.23% |
| 10-Year Change | -185.96% |
| Growth Volatility | 412.48 |
Revance Therapeutics, Inc. - Net Assets Trend (2011–2023)
This chart illustrates how Revance Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Revance Therapeutics, Inc. (2011–2023)
The table below shows the annual net assets of Revance Therapeutics, Inc. from 2011 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-151.60 Million | -1303.21% |
| 2022-12-31 | $12.60 Million | -81.60% |
| 2021-12-31 | $68.47 Million | -81.71% |
| 2020-12-31 | $374.29 Million | +65.99% |
| 2019-12-31 | $225.49 Million | +54.85% |
| 2018-12-31 | $145.62 Million | -45.83% |
| 2017-12-31 | $268.85 Million | +51.83% |
| 2016-12-31 | $177.07 Million | -30.08% |
| 2015-12-31 | $253.25 Million | +43.59% |
| 2014-12-31 | $176.37 Million | +211.95% |
| 2013-12-31 | $-157.55 Million | +27.31% |
| 2012-12-31 | $-216.73 Million | -39.39% |
| 2011-12-31 | $-155.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Revance Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 191829300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $88.00K | % |
| Other Comprehensive Income | $14.00K | % |
| Other Components | $1.93 Billion | % |
| Total Equity | $-151.60 Million | 100.00% |
Revance Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Revance Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AXTRART_AXTRA FUTURE CITY
BK:AXTRART
|
$333.28 Million |
|
Blend Labs Inc
NYSE:BLND
|
$333.30 Million |
|
Trilogy Metals Inc
NYSE MKT:TMQ
|
$333.43 Million |
|
ProSiebenSat.1 Media SE
PINK:PBSFF
|
$333.44 Million |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
$333.19 Million |
|
Alivus Life Sciences Limited
NSE:ALIVUS
|
$333.13 Million |
|
Amorepacific Group
KO:002795
|
$333.07 Million |
|
Betagro Public Company Limited
F:J74
|
$333.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Revance Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 12,600,000 to -151,604,000, a change of -164,204,000 (-1303.2%).
- Net loss of 323,986,000 reduced equity.
- Share repurchases of 8,215,999 reduced equity.
- New share issuances of 100,183,000 increased equity.
- Other comprehensive income increased equity by 388,000.
- Other factors increased equity by 67,426,999.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-323.99 Million | -213.71% |
| Share Repurchases | $8.22 Million | -5.42% |
| Share Issuances | $100.18 Million | +66.08% |
| Other Comprehensive Income | $388.00K | +0.26% |
| Other Changes | $67.43 Million | +44.48% |
| Total Change | $- | -1303.21% |
Book Value vs Market Value Analysis
This analysis compares Revance Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-21.66 | $3.65 | x |
| 2012-12-31 | $-30.20 | $3.65 | x |
| 2013-12-31 | $-8.88 | $3.65 | x |
| 2014-12-31 | $9.10 | $3.65 | x |
| 2015-12-31 | $10.40 | $3.65 | x |
| 2016-12-31 | $6.30 | $3.65 | x |
| 2017-12-31 | $8.93 | $3.65 | x |
| 2018-12-31 | $4.03 | $3.65 | x |
| 2019-12-31 | $5.19 | $3.65 | x |
| 2020-12-31 | $6.45 | $3.65 | x |
| 2021-12-31 | $1.01 | $3.65 | x |
| 2022-12-31 | $0.17 | $3.65 | x |
| 2023-12-31 | $-1.79 | $3.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Revance Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -138.43%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-280.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -8054.40% | 0.01x | 0.00x | $-29.31 Million |
| 2012 | 0.00% | -8125.38% | 0.05x | 0.00x | $-36.59 Million |
| 2013 | 0.00% | -8500.49% | 0.03x | 0.00x | $-36.69 Million |
| 2014 | -35.67% | -16427.42% | 0.00x | 1.09x | $-80.55 Million |
| 2015 | -29.01% | -24492.00% | 0.00x | 1.09x | $-98.80 Million |
| 2016 | -50.41% | -29756.67% | 0.00x | 1.15x | $-106.98 Million |
| 2017 | -44.85% | -46025.57% | 0.00x | 1.10x | $-147.47 Million |
| 2018 | -97.90% | -3823.22% | 0.02x | 1.55x | $-157.13 Million |
| 2019 | -69.28% | -37824.94% | 0.00x | 1.51x | $-178.77 Million |
| 2020 | -75.37% | -1840.71% | 0.02x | 1.92x | $-319.52 Million |
| 2021 | -418.90% | -368.68% | 0.15x | 7.76x | $-293.67 Million |
| 2022 | -2828.75% | -268.87% | 0.23x | 46.18x | $-357.68 Million |
| 2023 | 0.00% | -138.43% | 0.49x | 0.00x | $-308.83 Million |
Industry Comparison
This section compares Revance Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Revance Therapeutics, Inc. (RVNC) | $-163.03 Million | 0.00% | N/A | $333.19 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |